Navigation Links
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Date:5/21/2013

ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein," will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology during the Developmental Therapeutics - Immunotherapy Oral Abstract Session on Monday, June 3 at 4:15 – 4:30 PM.  The presentation will describe the results of a first-in-human study of MacroGenics' next-generation anti-HER2 monoclonal antibody, margetuximab, which is being developed to treat HER2-expressing tumors.  

MacroGenics has optimized the Fc region of margetuximab to increase cancer cell killing via Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).  Margetuximab also has shown improved control of tumor growth in human tumor xenograft models in mice as compared to that of anti-HER2 antibodies with a wild type Fc region.  A development goal for margetuximab is to enable the treatment of a broader population of patients than those eligible for treatment with current HER2-targeted therapies.

MacroGenics also announced that the first patient has received study drug in a Phase 2 clinical study evaluating margetuximab in patients with metastatic breast cancer.  This study is designed to evaluate the activity of margetuximab in up to 41 patients with metastatic breast cancer whose tumors express a moderate level of the oncoprotein, HER2, represented by a 2+ score by immunohistochemistry.  These tumors must also lack evidence of HER2 gene amplification as determined by FISH testing.  The trial is being conducted at six sites across the United States.  For more information on the clinical trial, please see www.clinicaltrials.gov.

"To date, the results of our Phase 1 s
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
2. Revolutionary Science Announces New Automatic and Manual Colony Counting Products
3. Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing
4. SoundConnect Announces Microsoft Lync Release in Canada
5. GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit
6. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
7. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
8. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
9. DNA Genotek Inc. Announces Spit for Africa Program
10. Metabolic Solutions Development Company announces publication of data describing a new drug target for diabetes
11. Discovery Labs Announces Completion of $14.25 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... YORK , July 28, 2015 Deerfield ... Deerfield Healthcare Innovations Fund, L.P., which will invest in ... interventions in genetic diseases, cancer, and orphan diseases. The ... can transform how therapeutics are developed and improve the ... fund, one of the largest healthcare-focused venture funds in ...
(Date:7/28/2015)... NEWPORT BEACH, Calif. , July 28, 2015 ... company, announced that it has hit a milestone ... Putty. Signafuse was FDA 510(k) cleared in early ... standalone use in posterolateral spine fusion procedures.  This ... graft products, as less than 6% of new ...
(Date:7/28/2015)... Israel , July 28, 2015 ... medicine company utilizing its proprietary plant-based rhCollagen technology ... Shurtz has been appointed Senior Director of Business ... (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... in marketing, regulatory and business strategy. Prior to ...
(Date:7/27/2015)... , July 27, 2015 /PRNewswire/ - Quest PharmaTech Inc. ... developing and commercializing products for the treatment of cancer, ... announces that it has closed a $1,000,000 unit offering ... of 16,666,667 units of the Company at a price ... one common share and one common share purchase warrant.  ...
Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Revolutionary Bone Graft Exceeds Expectations 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Quest PharmaTech Closes $1,000,000 Private Placement 2
... ATHENS, Ga., March 23 ArunA Biomedical, ... Inc. of Edina, MN, giving Neuromics the right ... Human Neural Cells and Neural Culture Medium to ... )ArunA has an exclusive worldwide license to ...
... Horizon Therapeutics, a privately held biopharmaceutical company ... executive officer will present at InsideVenture,s Debut Conference, ... Therapeutics has been selected from over 170 nominations ... showcased to long-term investors through presentations and 1-on-1 ...
... Ohio, March 23 NanoLogix announces that veteran journalist ... in advance of major news. Scanlon,s addition to ... information flow to investors and media, and will aid ... Bill Scanlon brings 25 years of experience in ...
Cached Biology Technology:ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells 2Horizon Therapeutics Selected to Present at InsideVenture's Debut Investor Conference March 25-26, Santa Barbara, California 2Horizon Therapeutics Selected to Present at InsideVenture's Debut Investor Conference March 25-26, Santa Barbara, California 3NanoLogix Adds Noted Journalist Bill Scanlon to Provide Media Relations 2
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... Lukiw, PhD, Associate Professor of Neuroscience and Ophthalmology ... lead author of a paper identifying, for the first ... acid (RNA), once thought to be no more than ... Alzheimer,s disease. The paper, An NF-kB-sensitive micro RNA-146a-mediated inflammatory ...
... Americans have headed to the polls to elect their next ... Current Biology , a Cell Press publication, reveals how ... time they reach a consensus to go for the more ... stickleback fish preferred to follow larger over smaller leaders," said ...
... CHARLOTTESVILLE, VA (November 13, 2008) In a report now ... the December 2008 issue of the Journal of Urology, ... PhD and his colleagues have confirmed the accuracy and reliability ... for detecting low concentrations of sperm. Herr, a ...
Cached Biology News:LSUHSC research identifies key contributor to Alzheimer's disease process 2Fish choose their leaders by consensus 2Fish choose their leaders by consensus 3First at-home test for vasectomized men proves to be safe, accurate 2
Rab1A...
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
... Product Mouse monoclonal [SPM278] to ... Small cell lung carcinoma N592 live cells ... with Human. Not yet tested in other ... of the major glycoproteins of basement membrane, ...
Biology Products: